Sun Pharmaceutical Industries, Ltd. v. Novartis AG

Case Overview and Background

Parties and posture. Despite the "patent infringement litigation" framing, IPR2017-01929 is an inter partes review — an administrative validity challenge at the USPTO's Patent Trial and Appeal Board (PTAB) — not a district court suit. Petitioner Sun Pharmaceutical Industries, Ltd., joined by U.S. subsidiary Sun Pharmaceutical Industries, Inc. and Sun Pharma Global FZE (collectively "Sun"), is a major India-based generic drug manufacturer that had filed an ANDA to market a generic version of Novartis's Gilenya (fingolimod). Patent owner Novartis AG is the Swiss innovator/operating company that developed Gilenya; Novartis Pharmaceuticals Corporation was identified as the real party in interest after the '405 patent was assigned to it (Assignment at Reel 043314/Frame 0800). Sun filed the petition on August 16, 2017, together with a motion to join the then-pending Apotex IPR (IPR2017-00854), per the petition and PTAB records (IPR2017-00854, FWD, Paper 109).

Patent and accused technology. The sole patent at issue is U.S. Patent No. 9,187,405, "S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," issued November 17, 2015 to Peter C. Hiestand and Christian Schnell. Claims 1–6 cover a method of treating relapsing-remitting multiple sclerosis (RR-MS) by orally administering fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, or its hydrochloride salt) at a daily dosage of 0.5 mg "absent an immediately preceding loading dose regimen." This is the Orange Book-listed dosing-regimen patent protecting Gilenya — the first oral MS therapy and a multi-billion-dollar blockbuster. The "accused" activity is the ANDA filers' proposed manufacture and sale of 0.5 mg generic fingolimod, whose label would instruct administration at 0.5 mg daily without a loading dose — the very method the claims capture. Sun's petition challenged claims 1–6 on three grounds: obviousness over Kovarik (WO 2006/058316) + Thomson; obviousness over Chiba, Kappos 2005, and Budde; and anticipation by a 2010 phase III trial disclosure (Kappos 2010) (IPR2017-01929 Petition; institution decision, Paper 7).

Procedural history and why it matters. The Board — initially APJs Lora M. Green, Christopher M. Kaiser, and Robert A. Pollock — instituted review and granted joinder on October 2, 2017, then administratively terminated IPR2017-01929 under 37 C.F.R. § 42.72, ordering all further filings in IPR2017-00854 with Apotex as lead petitioner (Argentum, IPR2017-01550, and Teva/Actavis, IPR2017-01946, joined the same proceeding). Venue in the traditional sense is not at play — the PTAB sits in Alexandria, Virginia, and hears cases nationwide — but the IPR's real significance is its linkage to Hatch-Waxman ANDA litigation: the PTAB's Final Written Decision of August 7, 2018 (Paper 109, per the panel of Kaiser, Sawert, and Pollock) held that the petitioners "failed to show, by a preponderance of the evidence, that claims 1–6 of the '405 patent are unpatentable," finding the art taught away from a 0.5 mg no-loading-dose regimen and that the Kappos 2010 reference was not prior art to the 2006 priority date. That win prompted Novartis to sue the generic filers in the District of Delaware (18-cv-1038 vs. Apotex; 18-cv-1039 vs. Teva; 18-cv-1040 vs. Sun; 18-cv-1043 vs. Accord). On appeal, Sun and most co-petitioners settled and dismissed their appeals (Sun's appeal, No. 18-2230, was dismissed before argument), and the remaining Argentum appeal (No. 18-2273) was dismissed for lack of Article III standing.

Why the case is notable. This IPR sits at the center of the Gilenya patent-protection saga: it followed an earlier IPR (IPR2014-00784) that invalidated the related '283 composition patent, making the '405 method-of-use claims Novartis's last line of defense until December 2027 (with pediatric exclusivity). The case is also a textbook example of coordinated generic challengers using joinder under 35 U.S.C. § 315(c) — four nearly identical petitions consolidated into a single lead proceeding. Most significantly, the '405 patent's "absent an immediately preceding loading dose regimen" negative limitation later became the vehicle for a landmark Federal Circuit written-description ruling: in Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. (Fed. Cir. 2022, on rehearing), Chief Judge Moore's majority reversed the Delaware finding of validity and held the claims invalid for lack of written description, declaring that "silence is not disclosure" for a negative limitation; Novartis thereafter sought Supreme Court review. The IPR itself, however, ended in Novartis's favor — an outcome that, together with confidential settlements with Sun and other ANDA filers, delayed generic fingolimod entry for years and helped preserve billions in Gilenya sales.

Sources: IPR2017-01929 petition (patentdocs.typepad.com); PTAB institution decision (Paper 7) and IPR2017-00854 Final Written Decision (Paper 109) (ptablitigationblog.com / USPTO); DocketAlarm and ipverse/greyb docket summaries; PTAB Litigation Blog, "PTAB Upholds GILENYA™ Method of Treatment Patent, Prompting New ANDA Litigation" (July 2018); CourtListener, Argentum Pharms. LLC v. Novartis Pharms. Corp., No. 18-2273 (Fed. Cir. 2020); IPWatchdog, "CAFC Reverses January Decision Affirming Sufficient Written Description for Negative Claim Limitation" (June 21, 2022); Novartis press releases (Jan. 2022, June 2022). Note: the docket-captioned respondent varies between "Novartis AG" and "Novartis Pharmaceuticals Corporation" across sources, reflecting the assignment; the case status is Terminated/Joined with FWD.

Key Legal Developments and Outcome — Sun Pharmaceutical v. Novartis (Gilenya® / U.S. Patent No. 9,187,405)

Scope note

The case metadata you supplied is the PTAB IPR (IPR2017-01929, Sun Pharmaceutical Industries, Ltd. et al. v. Novartis AG, challenging U.S. Patent No. 9,187,405). There was no district-court "infringement litigation" captioned Sun v. Novartis — the infringement case was the reverse: Novartis Pharmaceuticals Corp. v. Sun Pharmaceutical Industries, Ltd. et al., No. 1:18-cv-01040 (D. Del.) (Judge Leonard P. Stark), one of a coordinated group of Hatch-Waxman ANDA cases asserting the same '405 patent. The IPR and the district-court cases are procedurally intertwined (settlements in the litigation drove dismissal of the IPR appeals). Below is the combined chronology.

---

1. Background and the parallel IPR (the proceeding in your metadata)

The patent. U.S. Patent No. 9,187,405 B2 ("S1P Receptor Modulators for Treating Relapsing-Remitting Multiple Sclerosis," Hiestand/Schnell, issued 2015-11-17, assigned to Novartis AG; later assigned to Novartis Pharmaceuticals Corp.) claims methods of treating RRMS by orally administering fingolimod HCl (Gilenya®) at a 0.5 mg daily dose "absent an immediately preceding loading dose regimen" — a negative limitation at the center of all the litigation. The '405 patent claims priority to a UK application filed 2006-06-27 and expires December 2027 (incl. pediatric exclusivity). It is listed in the Orange Book for Gilenya 0.5 mg.

IPR2017-01929 (Sun's petition) — filed 2017-08-16. Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE petitioned for IPR of claims 1–6, filing a substantially identical petition to Apotex's and a motion for joinder to Apotex Inc. v. Novartis AG, IPR2017-00854 (filed 2017-02-03; trial instituted 2017-07-18). The petition alleged claims 1–6 unpatentable under § 103 (Kovarik + Thomson; Chiba + Kappos 2005 + Budde) and anticipated under § 102 by Kappos 2010 (PatentDocs PTAB Life Sciences Report, Oct. 2017).

Institution and joinder — 2017-10-02. The Board (APJs Green, Kaiser, Pollock) instituted review on all three grounds and granted joinder with IPR2017-00854; IPR2017-01929 was administratively terminated under 37 C.F.R. § 42.72, with all further filings made in the lead case (IPR2017-00854) and Apotex as lead petitioner. The same petition/joinder pattern was followed by Argentum (IPR2017-01550, joined 2017-08-09) and Teva/Actavis (IPR2017-01946). (Paper 7; PatentDocs PTAB Life Sciences Report, 2017-10-24; ipverse/greyb IPR2017-01929 docket.)

Board discovery order — 2018-01-11. The Board ordered discovery under 37 C.F.R. § 41.51(b)(1) and briefing under § 41.52(b)(2) in the joined proceeding (Paper, Jan. 11, 2018).

IPR Final Written Decision — 2018-07-11. In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109, the Board held claims 1–6 were NOT shown unpatentable on any ground. Key findings: no prior art disclosed 0.5 mg daily fingolimod without a loading dose; the art "taught away"; and the 2010 Kappos reference was not prior art because the '405 patent's 2006 priority date was established. (PTAB Litigation Blog/Jones Day, July 30, 2018; FWD Paper 109.)

Sun's Federal Circuit appeal of the IPR — filed 2018-08-07. Sun appealed the FWD (Notice of Appeal, Paper 112, IPR2017-00854; Fed. Cir. Appeal No. 2018-2230). This is also the "termination" date on the IPR2017-01929 docket. (DocketAlarm copy of Sun's Notice of Appeal.)

---

2. District court infringement litigation (D. Del.)

Complaints filed — mid-July 2018. Immediately after the IPR FWD, Novartis Pharmaceuticals Corp. sued the ANDA filers in the District of Delaware asserting the '405 patent: 18-cv-1038 (Apotex), 18-cv-1039 (Teva), 18-cv-1040 (Sun Pharma — Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc., Sun Pharma Global FZE), and 18-cv-1043 (Accord Healthcare) — all before Judge Stark (LPS). Summonses in 18-cv-1040 issued 2018-07-13; pro hac vice motions granted 2018-07-24. (Unified Patents Docket Portal, 1:18-cv-01040.)

Answers/counterclaims. The generic defendants admitted their ANDA products would infringe the '405 method claims and counterclaimed for invalidity (anticipation, lack of written description, lack of enablement). The four cases were coordinated for pretrial purposes (common docket entries in 1038/1039/1040/1043).

Discovery/scheduling — Oct. 2018. After a discovery impasse, Judge Stark held a discovery/scheduling teleconference on 2018-10-16 and entered a consolidated scheduling order, protective order, and ESI order (oral orders of 2018-10-09/10/16; Unified Patents docket). Strategic significance: the coordinated schedule aligned the Sun, Apotex, Teva, and Accord cases for a common invalidity fight on written description of the negative "loading dose" limitation.

Preliminary injunction — 2019-06-24. In the coordinated lead case, Judge Stark granted Novartis a preliminary injunction barring the generics from launching generic fingolimod 0.5 mg. The court held the defendants' infringement admissions plus their failure to show a likelihood of invalidity (Kappos 2006 anticipation; § 112 written description and enablement) warranted the injunction (Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc., No. 18-1043, June 24, 2019; Stark, J.; reported in Bloomberg/IP Law Daily, June 26, 2019).

Sun's settlement — 2019/2020. Sun (with Aurobindo, Dr. Reddy's, Mylan/Viatris, Apotex, Teva, and Actavis) settled with Novartis. Under the confidential settlements, the ANDA filers could launch generics before the '405 patent's December 2027 expiration, with the entry date and terms confidential (Novartis press releases, Jan. 2022/Sept. 2022; Reuters via Financial Express, Oct. 14, 2022). Sun's settlement ended the D. Del. case as to Sun and mooted Sun's Federal Circuit IPR appeal: Appeal No. 2018-2230 was dismissed ("Teva, Actavis, and Sun settled before argument and Appeal Nos. 18-2260 … and 18-2230 (Sun) were dismissed, respectively"; Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp., Fed. Cir. No. 18-2273, slip op. at 1 n.1, decided Feb. 2020). Apotex likewise settled after argument (No. 18-2209 dismissed). No Markman ruling, trial, verdict, or fee award was reached in the Sun-specific case — it resolved by settlement, as did the Sun IPR appeal, so the PTAB's validity ruling was never reversed on the merits in Sun's appeal.

---

3. Later developments affecting the same '405 patent (Accord/HEC case) — final disposition of the patent

Because the user asked for "final disposition or present posture," note the patent's ultimate fate was decided in the parallel HEC litigation, not in the Sun case:

• 2020-08 (D. Del., bench trial): Judge Stark upheld the '405 patent as valid and infringed by HEC and entered a permanent injunction through December 2027 (Novartis press release, Jan. 4, 2022).
• 2022-01-03 (Fed. Cir., first appeal): A panel (O'Malley, Linn; Moore, J., dissenting) affirmed validity, holding the negative "loading dose" limitation satisfied § 112(a) written description (Novartis v. Accord Healthcare, Appeal No. 2021-1070; IPWatchdog, Jan. 4, 2022).
• 2022-06 (Fed. Cir., rehearing): A modified panel reversed, holding claims 1–6 invalid for lack of written description of the "absent an immediately preceding loading dose regimen" limitation — no "textual hook" in the original 2006 disclosure; silence was not disclosure (Novartis press release, Sept. 21, 2022; SLW IP blog).
• 2022-09-21: Fed. Cir. denied Novartis's rehearing petition; Novartis announced intent to petition the Supreme Court.
• 2022-09-29: Chief Justice Roberts temporarily stayed the mandate.
• 2022-10-13/14: The Supreme Court declined to intervene, lifting the stay and clearing generic launches (Reuters/Financial Express, Oct. 14, 2022). Generic fingolimod entered the U.S. market thereafter.

---

4. Outcome summary for the Sun v. Novartis matter specifically

• IPR2017-01929 (PTAB): Petition granted in part via institution on all grounds; case joined into IPR2017-00854 and administratively terminated (2017-10-02); claims 1–6 upheld in the Final Written Decision (2018-07-11).
• Sun's Fed. Cir. appeal (2018-2230): Dismissed after settlement (2019–2020) — no merits decision.
• D. Del. infringement case (18-cv-1040): Filed July 2018; preliminary injunction granted against the generics June 2019; resolved by confidential settlement with Novartis — Sun obtained a licensed/agreed generic entry date before the December 2027 patent expiration, and the case was dismissed. No trial, verdict, claim-construction opinion, or fee award in the Sun-specific action.
• Bottom line: Novartis won at the PTAB (claims valid) and won the D. Del. preliminary injunction, but the commercial outcome was a negotiated early-entry settlement with Sun and most other generics; and the '405 patent was ultimately invalidated in 2022 by the Federal Circuit (on rehearing in the HEC case) for lack of written description of the negative loading-dose limitation, after which the Supreme Court declined review — opening the U.S. generic market for fingolimod 0.5 mg.

Sourcing caveat: Exact dates for Sun's answer, the settlement stipulation, and the dismissal order in 18-cv-1040 are not publicly itemized in the sources retrieved; those events are described here as "2018" and "2019/2020" based on the coordinated docket, the Federal Circuit's standing opinion in Argentum (No. 18-2273), and Novartis/Reuters reporting. The PTAB dates, the June 24, 2019 PI, the July 11, 2018 FWD, and the 2022 Federal Circuit/Supreme Court dates are well sourced as cited above.

Important framing note

IPR2017-01929 is not a district court patent infringement case — it is an inter partes review before the PTAB, so there is no "plaintiff" in the technical sense. The adversarial roles are Petitioner (Sun Pharmaceutical Industries, Ltd., together with co-petitioners Sun Pharmaceutical Industries, Inc. and Sun Pharma Global FZE, collectively "Sun") and Patent Owner (Novartis AG). Below is the counsel of record for the Sun entities (the party the user's question treats as "plaintiff"). For the record, the parallel district court Hatch-Waxman infringement suit involving the same '405 patent is Novartis Pharmaceuticals Corp. v. Sun Pharmaceutical Industries, Ltd., et al., No. 1:18-cv-01040 (D. Del., filed July 13, 2018), where Novartis is the plaintiff and Sun is the defendant — if that is the case the user actually meant, the parties are reversed (I did not verify the district court docket's counsel list, so I won't name them).

Counsel of record for Sun (Petitioner) in IPR2017-01929

The governing appointment is Sun's Power of Attorney filed with the Petition on August 16, 2017 (Paper 2, IPR2017-01929; PTACTS / PTAB filing), which designates:

1. Samuel S. "Sam" Park — Lead Counsel

• Firm: Winston & Strawn LLP, 35 W. Wacker Drive, Chicago, IL 60601 (USPTO Reg. No. 59,656; admitted IL, NY, USPTO).
• Role: Lead counsel for Petitioners Sun in IPR2017-01929.
• Source: Sun's Power of Attorney (Aug. 16, 2017); his Sept. 29, 2017 email to the Board ("I am the lead counsel for Petitioners Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE ('Sun') in IPR2017-01929"); the Board's Oct. 2, 2017 Institution & Joinder Decision listing "FOR PETITIONER SUN PHARMA: Samuel Park, Winston & Strawn LLP"; and the June 4, 2018 oral-hearing transcript in the joined proceeding (IPR2017-00854, Paper 108) where Park appeared for all Sun entities.
• Experience note: Winston & Strawn IP litigator who led Sun's PTAB challenge to Novartis's Gilenya (fingolimod) '405 patent; he handled Sun's joinder into the lead Apotex IPR and oral argument in the joined trial.

2. Sharick Naqi — Back-up Counsel (pro hac vice)

• Firm: Winston & Strawn LLP, 35 W. Wacker Drive, Chicago, IL 60601 (snaqi@winston.com).
• Role: Back-up counsel, designated "to be admitted" pro hac vice in Sun's Power of Attorney.
• Experience note: Winston & Strawn IP litigator (Hatch-Waxman/PTAB practice); no additional well-sourced case history verified for this specific proceeding.

3. Charles B. Klein — Back-up Counsel (pro hac vice)

• Firm: Winston & Strawn LLP, 1700 K Street, N.W., Washington, D.C. 20006-3817 (cklein@winston.com).
• Role: Back-up counsel, designated "to be admitted" pro hac vice in Sun's Power of Attorney.
• Experience note: Senior Winston & Strawn partner (former DOJ official) with a substantial appellate and complex-litigation practice, including life-sciences disputes; specific IPR-related experience in this case is not separately documented in the docket entries I found.

Procedural disposition (for context)

• Sun filed its Petition and a motion to join IPR2017-00854 on August 16, 2017.
• On October 2, 2017, the Board instituted IPR on all three grounds and granted joinder with the lead proceeding, IPR2017-00854 (Apotex Inc. v. Novartis AG), then administratively terminated IPR2017-01929 under 37 C.F.R. § 42.72; all further filings were made in IPR2017-00854.
• The Final Written Decision issued August 7, 2018 in the joined case (IPR2017-00854, Paper 109), which is the "final written decision" reflected in the case summary. Sun's related Federal Circuit appeal (No. 18-2230) was dismissed after settlement; the surviving appeal by Argentum was dismissed for lack of Article III standing (Argentum Pharmaceuticals LLC v. Novartis Pharms. Corp., Fed. Cir. 2020).

Patent Owner's counsel (Novartis side, for completeness): Jane M. Love, Ph.D. (lead, Gibson Dunn & Crutcher, New York) and Robert W. Trenchard (back-up, Gibson Dunn, New York), per Novartis's Mandatory Notices filed Sept. 5, 2017.

Caveats: The Power of Attorney source I located confirms the three Winston & Strawn attorneys above; if Sun later updated its mandatory notices in the joined case (e.g., adding local or additional back-up counsel), I did not locate a separate Sun-specific update — the May 7, 2018 updated mandatory notices I found in IPR2017-00854 were filed by Teva/Actavis (Kirkland & Ellis: Eugene Goryunov, Amanda Hollis, Gregory Springsted), not Sun. No filings in IPR2017-01929 appear to be sealed, and no additional counsel could be verified from the public docket.

Important framing note

Despite the caption in the metadata, IPR2017-01929 is not a district court patent infringement suit — it is an inter partes review before the PTAB challenging U.S. Patent No. 9,187,405 (the Gilenya® dosing patent). The "defendant" in that posture is the patent owner, Novartis AG (with Novartis Pharmaceuticals Corporation identified as the real party in interest; Novartis AG assigned the '405 patent to NPC on August 16, 2017). Sun's IPR was joined to lead case IPR2017-00854 (Apotex Inc. v. Novartis AG) by decision of Oct. 2, 2017, and IPR2017-01929 was administratively terminated under 37 C.F.R. § 42.72; the Final Written Decision issued in the joined proceeding (terminated Aug. 7, 2018).

Counsel of record for patent owner/defendant Novartis

1. Jane M. Love, Ph.D. — Lead Counsel

• Firm/office: Gibson, Dunn & Crutcher LLP, New York office (200 Park Avenue, 47th Floor, New York, NY 10166); USPTO Reg. No. 42,812; jlove@gibsondunn.com.
• Experience: Gibson Dunn IP partner who represented Novartis as patent owner across the Gilenya® IPRs on the '405 patent; she argued for Novartis as appellee in Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corp., 956 F.3d 1374 (Fed. Cir. 2020), the appeal from these joined IPRs (IPR2017-00854, -01550, -01929, -01946). She was the designated lead counsel in Novartis's mandatory notices filed in the related '405 patent proceedings (e.g., IPR2017-01946, Sept. 5, 2017) and is the signatory on the patent owner's filings in the joined IPR2017-00854 case.

2. Robert W. Trenchard — Back-up Counsel (pro hac vice)

• Firm/office: Gibson, Dunn & Crutcher LLP, New York office (200 Park Avenue, 47th Floor, New York, NY 10166); rtrenchard@gibsondunn.com.
• Experience: Gibson Dunn litigation partner with extensive first-chair life-sciences patent litigation experience before district courts and the PTAB; per his firm bio, he represented Novartis as patent owner in the successful IPR trial on the Gilenya® dosing method-of-use patent and co-led the subsequent Delaware ANDA litigation (23 filers) with Dr. Love. He is listed as "also represented by" counsel for Novartis on the Federal Circuit appeal (956 F.3d 1374).

Verification notes

• The patent owner's Mandatory Notices and Power of Attorney designating Love and Trenchard were filed September 5, 2017 (PTAB docket, IPR2017-01929, "PO Mandatory Notice" / "PO Power of Attorney" papers; see also the PTACTS/PTAB document download for the companion IPR2017-01946 mandatory notices naming the same two Gibson Dunn attorneys).
• The Board's Decision Instituting IPR2017-01929 and Granting Motion for Joinder (IPR2017-00854, Paper 24, Oct. 2, 2017) lists "FOR PATENT OWNER: Jane M. Love — GIBSON, DUNN & CRUTCHER LLP."
• Certificates of service in the joined case (e.g., IPR2017-00854, Paper 96) served Novartis at the correspondence address of Jane M. Love, Ph.D. and Robert W. Trenchard, Gibson Dunn.
• No in-house Novartis counsel, local counsel, or additional of-counsel appearances were identified in the public PTAB record for IPR2017-01929 itself; no filings were sealed with respect to counsel. If the user actually intends a parallel district court infringement case (e.g., Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC, N.D. Cal. 5:21-cv-03397, or the Delaware ANDA actions), a separate counsel-of-record search on those dockets would be needed — Gibson Dunn also represents Novartis in those actions.